The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 56
- 主要终点
- PK Profile of Dexmedetomidine
研究概览
简要总结
This study is being conducted to determine what dexmedetomidine does to the body and in turn, what how the body handles the medication. This medication, for the purpose of this trial, is used as a short-term sedative for infants who are immediately post-operative from cardiac surgery and have a breathing tube and are breathing with the assistance of a mechanical ventilator or breathing machine.
详细描述
This is a single center, dose escalation study of a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours in infants who are immediately post-operative from cardiac surgery and require tracheal intubation with mechanical ventilation in the post-operative period. Three bolus doses and infusion doses will be administered to a total of 36 evaluable patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Month 至 24 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be greater or equal to one month or less than or equal to 24 months of age.
- •Post operative from cardiac surgery with tracheal intubation/mechanical ventilation in the immediate post-op period.
- •Planned tracheal extubation within 24 hours post-operatively.
- •Adequate renal function(1-12 months old creatinine less than or equal to 0.6mg/dL and >12 months to 24 months creatinine < or= to 1.0mg/dL)
- •Adequate liver function(Total bilirubin < or= 1.5mg/dL and ALT 1-12 months < or = to 165 U/L and > 12 months to 24 months < or = to 90 U/L)
- •Isolated heart surgery
- •Informed consent
排除标准
- •Patients who have received another investigational drug within the past 30 days.
- •Receiving continuous infusions of muscle relaxants in the postoperative setting.
- •Patients whoo have a positive blood culture without a subsequent negative culture or other evidence of ongoing serious infection.
- •Patients, who, int he opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
- •Patients who show signs or symptoms of elevated intracranial pressure.
- •Post-operative hypotension based on age.
- •Preexisting bradycardia based on age.
- •Heart block
- •Weight < 5kg
- •Patients, who in the opinion of the investigator, are not appropriate candidates for an investigational drug study.
研究组 & 干预措施
Dosing level
A predetermined dose of Dexmedetomidine
干预措施: Dexmedetomidine (Drug)
结局指标
主要结局
PK Profile of Dexmedetomidine
时间窗: after start of infusion (0.5, 1, 2, 4-6 hours), immediately prior to end of infusion and following end of infusion (0.25, 0.5, 1, 2, 4, 8, 12, 15-18 hours)
This study measured the concentration of dex in the body and used those concentrations to determine how quickly the body metabolizes and eliminates dex(concentration-time or pharmacokinetic profile).The concentration of dex in the body is determined through serial blood sampling while administering dex and following discontinuation.
次要结局
未报告次要终点
研究者
Athena Zuppa
Attending Physician
Children's Hospital of Philadelphia